Opendata, web and dolomites

UshTher SIGNED

Clinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "UshTher" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE TELETHON 

Organization address
address: VIA VARESE 16/B
city: ROMA
postcode: 185
website: www.telethon.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.ushther.eu/
 Total cost 5˙998˙515 €
 EC max contribution 5˙998˙515 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE TELETHON IT (ROMA) coordinator 1˙783˙642.00
2    REITHERA SRL IT (ROMA) participant 2˙566˙669.00
3    UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI IT (CASERTA) participant 700˙567.00
4    GENOSAFE SAS FR (EVRY) participant 527˙952.00
5    HET ROTTERDAMS OOGHEELKUNDIG INSTITUUT BV NL (ROTTERDAM) participant 137˙445.00
6    INSTITUTO INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ ES (MADRID) participant 136˙645.00
7    ASSOCIATION GENETHON FR (EVRY) participant 91˙068.00
8    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA IT (MILANO) participant 54˙525.00
9    STICHTING OOGZIEKENHUIS ROTTERDAM NL (ROTTERDAM) participant 0.00

Map

 Project objective

Usher syndrome (USH) is the most common combination of deafness and blindness due to retinitis pigmentosa. USHIB caused by mutations in the large MYO7A gene, is among the most severe and frequent forms of USH. While deafness can be improved with cochlear implants, blindness remains untreatable. Retinal gene therapy with AAV vectors is both safe and effective in humans, however it is limited by AAV cargo capacity which would not allow transfer of the large MYO7A expression cassette. UshTher objective is to test the safety and efficacy of a highly innovative gene therapy approach (dual AAV) in the retina of USHIB patients. The projects builds on data previously obtained by the coordinator that a single combined subretinal administration of dual AAV vectors, each packaging one of the two halves of a MYO7A expression cassette, results in MYO7A reconstitution and therapeutic efficacy in a mouse model of USHIB. This has received the Orphan Drug Designation from the European Medicines Agency. It would be the first time the dual AAV vector approach is tested in humans. Towards this ambitious objective, UshTher has assembled a very competitive consortium with leaders in the fields of retinal gene therapy from bench to bedside including SMEs with expertise in the development of gene therapy products. The planned activities span from manufacturing of clinical –grade dual AAV vectors to non clinical safety, biodistribution and expression studies performed under good laboratory practices up to performing a multicenter, multinational clinical trial which envisages subretinal administrations of dual AAV vectors in twelve USHIB patients. UshTher success will set the basis for a cure for USHIB retinitis pigmentosa, and for testing dual AAV vectors in other rare and more common conditions which require delivery of large genes, thus overcoming one of the major limitations of in vivo gene therapy.

 Deliverables

List of deliverables.
Report Planned communication activity Documents, reports 2020-04-07 22:46:13
Connection with patient organization Documents, reports 2020-04-07 22:46:13
Website and intranet portal Websites, patent fillings, videos etc. 2020-04-07 22:46:14
Official logo of UshTher Documents, reports 2020-04-07 22:46:14
Flyer publication Documents, reports 2020-04-07 22:46:14
Contact database of relevant representatives of stakeholder groups Documents, reports 2020-04-07 22:46:13
Detailed dissemination plan Documents, reports 2020-04-07 22:46:13
Social Network strategy plan Websites, patent fillings, videos etc. 2020-04-07 22:46:14
Periodic report on project dissemination and exploitation Documents, reports 2020-04-07 22:46:13

Take a look to the deliverables list in detail:  detailed list of UshTher deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "USHTHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "USHTHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More